2 days Ago By Defense World Staff
Charles Schwab Investment Management Inc. grew its stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX – Free Report) by 13.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.
The institutional investor owned 112,021 shares of the company’s stock after buying an additional 12,961 shares during the period. Charles Schwab Investment Management Inc. owned 0.
14% of MeiraGTx worth $682,000 at the end of the most recent reporting period. A number of other hedge funds have also modified their holdings of the company. Janney Montgomery Scott LLC purchased a new stake in shares of MeiraGTx during the fourth quarter worth about $459,000.
Barclays PLC raised its holdings in shares of MeiraGTx by 107.1% during the 3rd quarter. Barclays PLC now owns 147,827 shares of the company’s stock worth $618,000 after acquiring an additional 76,437 shares in the last quarter.
State Street Corp boosted its position in shares of MeiraGTx by 0.9% during the 3rd quarter. State Street Corp now owns 574,727 shares of the company’s stock valued at $2,397,000 after acquiring an additional 5,251 shares during the last quarter.
Garden State Investment Advisory Services LLC bought a new stake in MeiraGTx in the third quarter worth $1,636,000. Finally, JPMorgan Chase & Co. raised its stake in MeiraGTx by 1.
2% during the third quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company’s stock valued at $1,429,000 after purchasing an additional 4,186 shares in the last quarter.
67.48% of the stock is currently owned by institutional investors. MeiraGTx Stock Down 7.
5 %NASDAQ MGTX opened at $6.78 on Tuesday. The company has a quick ratio of 2.
34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86.
MeiraGTx Holdings plc has a 52 week low of $3.85 and a 52 week high of $8.75.
The firm has a market capitalization of $534.64 million, a price-to-earnings ratio of -5.60, a PEG ratio of 0.
37 and a beta of 1.23. The company has a fifty day moving average of $6.
84 and a two-hundred day moving average of $6.10. MeiraGTx (NASDAQ:MGTX – Get Free Report) last released its quarterly earnings results on Thursday, March 13th.
The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.
02). MeiraGTx had a negative return on equity of 146.38% and a negative net margin of 633.
05%. The firm had revenue of $21.39 million for the quarter, compared to analysts’ expectations of $1.
50 million. On average, analysts predict that MeiraGTx Holdings plc will post -1.48 earnings per share for the current year.
Analyst Upgrades and DowngradesA number of analysts have recently weighed in on MGTX shares. Chardan Capital restated a “buy” rating and issued a $36.00 target price on shares of MeiraGTx in a report on Monday, February 24th.
Royal Bank of Canada boosted their price objective on MeiraGTx from $11.00 to $13.00 and gave the stock an “outperform” rating in a research note on Monday, March 17th.
Get Our Latest Report on MeiraGTxInsider ActivityIn other MeiraGTx news, CEO Alexandria Forbes sold 35,839 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total value of $231,878.
33. Following the transaction, the chief executive officer now owns 1,395,102 shares of the company’s stock, valued at $9,026,309.94.
This represents a 2.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Also, CFO Richard Giroux sold 24,000 shares of MeiraGTx stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $6.29, for a total value of $150,960.
00. Following the sale, the chief financial officer now owns 849,947 shares of the company’s stock, valued at approximately $5,346,166.63.
This trade represents a 2.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here.
Insiders own 8.40% of the company’s stock. MeiraGTx Company Profile (Free Report)MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.
The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.See AlsoFive stocks we like better than MeiraGTxBest Stocks Under $5.003 Buyable Stocks With Solid Bottoms Ready to ReboundHow Investors Can Identify and Successfully Trade Gap-Down StocksAdvantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads StarStock Analyst Ratings and Canadian Analyst RatingsRobotaxi News: What Tesla and Lyft Headlines Mean for SharesWant to see what other hedge funds are holding MGTX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for MeiraGTx Holdings plc (NASDAQ:MGTX – Free Report)..
